LAUSR

STUDY OBJECTIVES There is strong evidence that sleep disturbances are an independent risk factor for the development of chronic pain conditions. The mechanisms underlying this association, however, are still not well understood. We examined the effect of experimental sleep disturbances on three pathways involved in pain initiation/resolution: (1) the central pain-inhibitory pathway, (2) the cyclooxygenase (COX) pathway, and (3) the endocannabinoid (eCB) pathway. METHODS Twenty-four healthy participants (50% females) underwent two 19-day long in-laboratory protocols in randomized order:(a) an experimental sleep disturbance protocol consisting of repeated nights of short and disrupted sleep with intermittent recovery sleep; and (b) a sleep control protocol consisting of nights with an 8-hour sleep opportunity. Pain inhibition (conditioned pain modulation, habituation to repeated pain), COX-2 expression at monocyte level (LPS-stimulated and spontaneous), and eCBs (AEA, 2-AG, DHEA, EPEA, DTEA) were measured every other day throughout the protocol. RESULTS The central pain-inhibitory pathway was compromised by sleep disturbances in females, but not in males (p<0.05 condition*sex effect). The COX-2 pathway (LPS-stimulated) was activated by sleep disturbances (p<0.05 condition effect), and this effect was exclusively driven by males (p<0.05 condition*sex effect). With respect to the eCB pathway, DHEA was higher (p<0.05 condition effect) in the sleep disturbance compared to the control condition, without sex-differential effects on any eCBs. CONCLUSIONS These findings suggest that central pain-inhibitory COX mechanisms through which sleep disturbances may contribute to chronic pain risk are sex specific, implicating the need for sex-differential therapeutic targets to effectively reduce chronic pain associated with sleep disturbances in both sexes.